에 대한 최신 뉴스 Qiagen (NYSE:QGEN) 주식

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

Wall-Street-ai7-1

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

<ul>
<li>Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases</li>
<li>Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market</li>
<li>Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN's leading genetic databases COSMIC and HGMD</li>
</ul>

News

QIAGEN To Acquire GENOOX For $70M

Management

QIAGEN To Elect Stephen H. Rusckowski As Chairman; To Succeed Lawrence A. Rosen

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) FY2025 expected to be more than $2.35 vs $2.49 Est..

Guidance

Qiagen FY2025  Reaffirms EPS Of $2.35 CER Vs $2.49 Est

Dividends

Buybacks

QIAGEN At Annual General Meeting Proposes To Introduce A Dividend As Expansion Of Capital Allocation Strategy, Also Seek Authorization For A New $500M Share Repurchase

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.56 by 1.79 percent. This is a 17.02 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $483.00 million which missed the analyst consensus estimate of $507.25 million by 4.78 percent. This is a 5.28 percent increase over sales of $458.80 million the same period last year.

Earnings Misses

Qiagen Q1 Adj. EPS $0.55 Misses $0.56 Estimate, Sales $483.00M Miss $507.25M Estimate

QIAGEN To Propose Initiation Of Annual Cash Dividend Consisting Of $0.25 Per Ordinary Share At Next Annual General Meeting

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

<ul>
<li>QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing</li>
<li>Expansion underscores the commitment of QIAGEN to help accelerate the development of safe and effective biotherapeutics</li>
<li>New solutions support high-precision analytics for process development, batch release and regulatory compliance and enable a standardized workflow</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.
This expanded offering supports standardized, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organizations (CDMO) and therapy developers in CGT manufacturing.
"Cell and gene therapy developers face increasing demands for precise, scalable solutions to help ensure therapy safety and efficacy," said Justus Krause-Harder, Vice President and Head of Molecular Tools &amp; Oncology at QIAGEN. "With our expanded dPCR portfolio, we are not only meeting the needs of lentivirus-based therapies but also reaffirming our long-term commitment as a partner for quality control in CGT development and manufacturing."
The additions to QIAGEN's offering of dPCR solutions for lentiviral vectors and their characterization include:
<ul>
<li>The QIAcuity RCL Quant Kit detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe.</li>
<li>The new QIAcuity CGT dPCR assays, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell). The assays offer superior accuracy, reproducibility and speed on the QIAcuity Digital PCR System and enable singleplex and multiplex applications for a streamlined, high-throughput workflow. Together with QIAcuity nanoplates and dedicated master mixes, these assays deliver absolute quantification of viral titer (the concentration of virus particles in a sample) and vector copy number determination, which are crucial for biopharmaceutical manufacturing and quality control processes.</li>
<li>The new CGT Lentivirus Lysis Kit and protocol, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability. It supports standardized titer quantification from lentivirus particles, promotes robust QC and improved operating procedures, and is ideal for drug development and manufacturing in CGT.</li>
</ul>
These new solutions join the growing portfolio of cell and gene therapy dPCR assays for the biopharma market, including residual DNA quantification kits for commonly used production cell lines such as Human Embryonic Kidney 293 (HEK293), E. coli, and Chinese Hamster Ovary (CHO) cells, mycoplasma quantification kit, adeno-associated virus (AAV) application, viral titer assays and solutions to determine viral vector integrity.

Biotech

General

QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control

Baird analyst Catherine Schulte maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Neutral and raises the price target from $42 to $43.

Price Target

Analyst Ratings

Baird Maintains Neutral on Qiagen, Raises Price Target to $43

<a href="https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen" title="https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen">https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen</a>

Rumors

Watching Qiagen N.V.; Hearing Fivespan Is Said To Build Stake In Life Sciences Group Qiagen

<ul>
<li>Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position</li>
<li>QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows</li>
<li>QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands</li>
</ul>
 &nbsp;

QIAGEN To Launch Three New Sample Prep Instruments By 2026, Expanding Automation From Low To High Throughput Labs

<ul>
<li>QIAGEN provides clinical decision support through its QIAGEN Clinical Insights Interpret One software for expanded Marsden360 liquid biopsy service now offering ESR1 circulating tumor DNA testing for breast cancer patients</li>
<li>Marsden360 offers a minimally invasive alternative to tissue biopsies, enabling rapid identification of mutations in patients with solid tumors</li>
<li>QIAGEN Clinical Insight Interpret One enables reliable variant interpretation by combining AI and human curation, ultimately leading to actionable insights improving patient outcomes</li>
</ul>
 Redwood City, California -- QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN and the leading provider of bioinformatics software and biomedical knowledge content, today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) Interpret One, is supporting The Royal Marsden National Health Service (NHS) Foundation Trust's new offering for ESR1 genomic testing, a mutation associated with breast cancer, as part of its workflow for Marsden360, an innovative liquid biopsy service.
On January 20, 2025, the NHS expanded its National Genomic Test Directory to include ESR1 circulating tumor DNA (ctDNA) testing for breast cancer patients. This milestone enables oncologists to detect ESR1 mutations through a simple blood test, guiding personalized treatment strategies for patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer.
Since its launch in 2021, Marsden360 is available for private and clinical trial patients at the Royal Marsden Hospital, a specialist oncology hospital in London, United Kingdom. The service has completed thousands of ctDNA tests as part of an NHS England national study and is advancing toward inclusion in the insurance-covered test directory.
Marsden360 is a blood-based test that analyzes 74 genes to detect genetic mutations in ctDNA, providing a minimally invasive alternative to traditional biopsies. The service enables oncologists to rapidly identify genetic changes in patients with solid tumors, guiding personalized treatment strategies - especially for cases where tissue biopsies are not feasible.
By integrating QCI Interpret One, clinicians gain unmatched accuracy, speed, and consistency in variant interpretation, allowing them to deliver high-confidence, actionable insights for precision oncology treatments.

QIAGEN's QCI Interpret One Selected By Royal Marsden NHS Foundation Trust To expand Marsden360 Liquid Biopsy Service For ESR1 Testing For Breast Cancer Patients

WIIM

Qiagen shares are trading higher following the company's prelim. Q1 results.

Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) shares are trading higher premarket on Monday. On Sunday, the company disclosed its preliminary results for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44658748/qiagen-delivers-strong-preliminary-q1-2025-results-exceeding-outlook-and-raises-full-year-2025-adj" rel="noreferrer noopener">first quarter of 2025</a>.
The company sees net sales growth of around 5% (+7% at constant exchange rates, CER) to about $483 million vs. consensus of $506.5 million.
The revenue figure surpassed the previously communicated outlook of about 3% CER growth (4% CER core business, excluding discontinued products such as NeuMoDx and Dialunox).
The company expects an adjusted EPS of at least $0.55 (vs. the street view of $0.56) in CER in the quarter, compared to prior guidance of about $0.50 CER.
Qiagen anticipates that the QuantiFERON latent TB test sales will increase by around 15% at CER, driven by the continued global shift from the traditional skin test to this reliable, modern, blood-based alternative.
The QIAstat-Dx syndromic testing system is expected to grow by over 35% CER, fueled by strong demand for respiratory panels and expansion in gastrointestinal and meningitis testing.
Both the QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business are projected to show high single-digit CER growth, reflecting strong adoption in research and clinical settings.
However, Sample Technologies sales are expected to decline by 1% CER, reflecting a cautious spending environment among some Life Sciences customers for instruments.
2025 Outlook: The company raised the adjusted EPS outlook to about $2.35 in CER from <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$2.28 prior (vs. consensus of $2.48)</a>.
The outlook reflects strong sales in the first quarter, expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.
Meanwhile, Qiagen reiterated the outlook for the adjusted operating income margin to be above 30% for the year.
QIAGEN now expects to achieve its mid-term target for an adjusted operating income margin of at least 31% significantly earlier than planned, well ahead of the original 2028 timeline.
This acceleration reflects stronger-than-expected performance improvements realized throughout 2024 and into 2025.
The company plans to release the first <a href="https://www.benzinga.com/earnings">quarter of 2025 results on May 7, 2025</a>.
Investors can gain exposure to the stock via&nbsp;Global X Genomics &amp; Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNOM#NASDAQ">GNOM</a>) and First Trust Nasdaq Lux Digital Health Solutions ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKG#NASDAQ">EKG</a>).
Price Action: QGEN shares are up 3.06% at $39.43 premarket at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44658456/sp500-fell-9-1-last-week-and-these-large-cap-stocks-were-obliterated-mar-31-apr-4" target="_blank" rel="noreferrer noopener">S&amp;P500 Fell 9.1% Last Week And These Large Cap Stocks Were Obliterated (Mar 31-Apr 4)</a></li>
</ul>
Photo: Shutterstock

Movers

GNOM

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

<ul>
<li>Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment</li>
<li>Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER)</li>
<li>On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target</li>
</ul>

Reported Sunday, QIAGEN Preliminary Q1 2025 Revenue ~$483M And Expects Adj. EPS Of At least $0.55 (Vs. $0.56 Est.); Raised 2025 EPS Target To ~$2.35 (Vs. $2.48 Est.) From Prior $2.28

Redburn Atlantic analyst Ed Ridley-Day downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Buy to Neutral.

Downgrades

Redburn Atlantic Downgrades Qiagen to Neutral

<ul>
<li>Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa</li>
<li>QIAprep&amp;amp Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance</li>
<li>Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure</li>
</ul>

QIAGEN's QIAprep Plasmodium Kit Supports Global Malaria Efforts With Enhanced Detection Of Mixed Infections And Parasite Strains

Zymo Research said it is pleased with the Court's ruling and expects that its antitrust claims will be further vindicated through discovery and trial.

Legal

Zymo Research Says Court Denied QIAGEN GmbH's Partial Motion To Dismiss And In The Alternative, To Stay Certain Counterclaims Brought By Zymo

QIAGEN Announced That The U.S. Food And Drug Administration (FDA) Has Cleared The QIAstat-Dx Gastrointestinal Panel 2 Mini B For Clinical Use, Further Strengthening Its Syndromic Testing Portfolio In The United States

QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technologyQuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide
<ul>
<li>QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology</li>
<li>QuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide</li>
</ul>

QIAGEN Files Lawsuit To Protect QuantiFERON Technology Amid Tuberculosis Testing Patent Dispute

Press Releases

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

QIAGEN announces plans for transition in leadership of Supervisory Board

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

Baird

Morgan Stanley

Jefferies

Wolfe Research

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" target="_blank" rel="noopener" data-google-interstitial="false">재무 실적</a>을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다.
애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.
<h3 class="wp-block-heading">‘주식 선택자의 해&#8217;: S&amp;P 500에서 10% 상승</h3>
골드만삭스의 애널리스트들은 2024년을 &#8220;주식 선택자의 해&#8221;라고 부르며, 변동성이 큰 실적 환경에서 선택적 투자의 중요성을 강조했다.
이 투자은행의 최신 전망에 따르면, 평균 S&amp;P 500 주식은 향후 12개월 동안 10%의 상승 잠재력을 가질 수 있다.
&#8220;우리는 반등 가능성을 보고 있다&#8221;고 마샬이 그의 노트에서 언급했다. &#8220;옵션 시장의 방향성 포지셔닝이 균형을 이루고 있어, 지난 분기 이맘때보다 훨씬 나은 설정이다.&#8221;
또한 이 애널리스트들은 최근 헤지 펀드와 소매 트레이더들 모두의 옵션 시장 활동이 감소하여, 투자자들이 3분기 실적 보고서와 다가오는 미국 선거를 준비하면서 &#8220;관망하는(wait-and-see)&#8221; 태도를 취하고 있음을 나타냈다.
<h3 class="wp-block-heading">실적 시즌의 변동성은 여전히 높다</h3>
골드만삭스는 실적 이벤트를 둘러싼 개별 주식의 변동성이 14년 만에 최고 수준에 있다고 강조했다.
인공지능(AI), 금리 그리고 다가오는 선거와 같은 주요 시장 논쟁이 이 추세를 주도하고 있으며, 이는 연말까지 계속될 것으로 예상된다.
&#8220;우리는 실적 발표일의 주가 변동이 여전히 높을 것으로 예상하며, 이는 시장의 주요 논쟁들이 주식 공간에서 승자와 패자를 만들어내기 때문이다,&#8221;라고 이 노트에 추가했다.
이러한 높은 변동성 속에서, 이 회사는 옵션 기반 전략을 계속 추천하며, 투자자들에게 실적 이벤트 전 옵션을 매수하고 실적 기간 사이에 옵션을 매도하여 가격 변동을 활용할 것을 권장했다.
<h3 class="wp-block-heading">골드만삭스가 3분기 실적에 대해 긍정적으로 평가한 18개 주식</h3>
골드만삭스의 애널리스트들은 실적 조정이 긍정적으로 작용할 수 있다고 믿는 18개의 주식을 선정했다. 이 주식들은 에너지, 금융, 헬스케어, 기술 등 다양한 부문에 걸쳐 있다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>실적 발표일</th>
</tr>
</thead>
<tbody>
<tr>
<td>갭 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>소비재</td>
<td>11월 15일</td>
</tr>
<tr>
<td>퍼미안 리소스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>에너지</td>
<td>11월 7일</td>
</tr>
<tr>
<td>씨티그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>금융</td>
<td>10월 15일</td>
</tr>
<tr>
<td>싱크로니 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>금융</td>
<td>10월 16일</td>
</tr>
<tr>
<td>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>헬스케어</td>
<td>10월 30일</td>
</tr>
<tr>
<td>보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>헬스케어</td>
<td>10월 23일</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>헬스케어</td>
<td>10월 31일</td>
</tr>
<tr>
<td>퀴아젠 NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>헬스케어</td>
<td>10월 30일</td>
</tr>
<tr>
<td>AZEK 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>산업재</td>
<td>11월 29일</td>
</tr>
<tr>
<td>ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>11월 1일</td>
</tr>
<tr>
<td>브로드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>12월 6일</td>
</tr>
<tr>
<td>델 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>11월 25일</td>
</tr>
<tr>
<td>클라비요 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
<tr>
<td>먼데이닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>11월 13일</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>11월 21일</td>
</tr>
<tr>
<td>스노우플레이크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>11월 29일</td>
</tr>
<tr>
<td>토스트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
<tr>
<td>셈프라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>유틸리티</td>
<td>11월 4일</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">골드만삭스가 3분기 실적에 대해 비관적으로 평가한 7개 주식</h3>
반대로, 이 투자은행은 3분기 실적에서 하향 조정의 영향을 받을 것으로 예상되는 7개 주식을 선정하여 투자자들에게 주의할 것을 권고했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>실적 발표일</th>
</tr>
</thead>
<tbody>
<tr>
<td>초이스호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>소비재</td>
<td>11월 7일</td>
</tr>
<tr>
<td>셰니에르 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>에너지</td>
<td>11월 1일</td>
</tr>
<tr>
<td>야누스 헨더슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>금융</td>
<td>10월 31일</td>
</tr>
<tr>
<td>라이온델바젤 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>소재</td>
<td>11월 1일</td>
</tr>
<tr>
<td>크로락스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>소비재</td>
<td>11월 1일</td>
</tr>
<tr>
<td>크래프트 하인즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>소비재</td>
<td>10월 30일</td>
</tr>
<tr>
<td>업스타트 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
</tbody>
</table>
</figure>
 
다음 글 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">연준의 굴스비가 인플레이션 상승을 경시하며, 경제학자들은 11월 금리 인하 발표에 대한 입장을 고수합니다.</a></li>
</ul>
이미지는 Midjourney를 통해 인공지능으로 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 '주식 선택자의 해'

Comments

Qiagen

뉴스

에 대한 최신 뉴스 Qiagen (NYSE:QGEN) 주식

금요일, 10월 11, 2024

뉴스

파트너 / 기고자

벤징가 글로벌